Literature DB >> 27576769

More Precise Imaging Analysis and Diagnosis of Moyamoya Disease and Moyamoya Syndrome Using High-Resolution Magnetic Resonance Imaging.

Le-Bao Yu1, Huan He2, Ji-Zong Zhao1, Rong Wang1, Qian Zhang1, Zhi-Yong Shi1, Jun-Shi Shao1, Dong Zhang3.   

Abstract

BACKGROUND: The diagnosis of moyamoya disease (MMD) is often uncertain. Moyamoya syndrome (MMS) is often misdiagnosed as MMD. High-resolution magnetic resonance imaging (HR-MRI) enables vessel wall assessment to obtain more precise diagnoses. The aim of this study was to determine the true etiologies of arterial steno-occlusion in patients with an angiographic diagnosis of MMD or MMS using HR-MRI.
METHODS: HR-MRI was performed in 21 adult patients with angiographically proven MMD or MMS. A definite diagnosis was based on the HR-MRI findings. The diagnoses made via the 2 different imaging technologies were compared, and significant findings were analyzed.
RESULTS: A total of 21 patients were enrolled, including 7 patients with angiographically proven MMD and 14 patients with angiographically proven MMS. Among the 7 patients with MMD, HR-MRI confirmed the diagnosis of MMD in 6; the remaining patient was considered to have atherosclerosis in the bilateral distal internal carotid arteries (ICAs) and the left middle cerebral artery. Among the 14 patients with MMS, HR-MRI confirmed MMD in 6 patients (including 2 patients with unilateral MMD), atherosclerosis in 5 patients (including 3 patients with bilateral atherosclerosis and 2 with unilateral atherosclerosis), arterial dissection of the left ICA in 1 patient, and MMD in the left cerebral hemisphere with atherosclerosis in the right hemisphere in 2 patients.
CONCLUSIONS: Differentiating MMD from MMS is difficult in certain situations, and HR-MRI may help provide a more in-depth understanding of MMD and MMS, thereby achieving a more reliable diagnosis. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-resolution magnetic resonance imaging; Intracranial atherosclerosis; Moyamoya disease; Moyamoya syndrome

Mesh:

Year:  2016        PMID: 27576769     DOI: 10.1016/j.wneu.2016.08.083

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Qualitative Assessment and Reporting Quality of Intracranial Vessel Wall MR Imaging Studies: A Systematic Review.

Authors:  J W Song; S C Guiry; H Shou; S Wang; W R Witschey; S R Messé; S E Kasner; L A Loevner
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

Review 2.  Progress in moyamoya disease.

Authors:  Shuling Shang; Da Zhou; Jingyuan Ya; Sijie Li; Qi Yang; Yuchuan Ding; Xunming Ji; Ran Meng
Journal:  Neurosurg Rev       Date:  2018-06-18       Impact factor: 3.042

3.  Current understanding of chronic total occlusion of the internal carotid artery.

Authors:  Baofeng Xu; Chao Li; Yunbao Guo; Kan Xu; Yi Yang; Jinlu Yu
Journal:  Biomed Rep       Date:  2017-12-18

4.  Plasticity of the bony carotid canal and its clinical use for assessing negative remodeling of the internal carotid artery.

Authors:  Yuki Oichi; Yohei Mineharu; Yuji Agawa; Takaaki Morimoto; Takeshi Funaki; Yasutaka Fushimi; Kazumichi Yoshida; Hiroharu Kataoka; Susumu Miyamoto
Journal:  PLoS One       Date:  2021-12-15       Impact factor: 3.240

5.  RNF213 R4810K Variant in Suspected Unilateral Moyamoya Disease Predicts Contralateral Progression.

Authors:  Taedong Ok; Yo Han Jung; Jinkwon Kim; Sang Kyu Park; Goeun Park; Sujee Lee; Kyung-Yul Lee
Journal:  J Am Heart Assoc       Date:  2022-07-25       Impact factor: 6.106

Review 6.  Characteristics of Moyamoya Disease in the Older Population: Is It Possible to Define a Typical Presentation and Optimal Therapeutical Management?

Authors:  Ignazio G Vetrano; Anna Bersano; Isabella Canavero; Francesco Restelli; Gabriella Raccuia; Elisa F Ciceri; Giuseppe Faragò; Andrea Gioppo; Morgan Broggi; Marco Schiariti; Laura Gatti; Paolo Ferroli; Francesco Acerbi
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.